PetMed Express (PETS) Expected to Release Earnings on Monday

PetMed Express (NASDAQ:PETS) is expected to announce its Q3 2026 results before the market opens on Monday, February 9th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Monday, February 9, 2026 at 4:00 PM ET.

PetMed Express Price Performance

Shares of NASDAQ PETS opened at $3.19 on Monday. PetMed Express has a 1-year low of $1.57 and a 1-year high of $5.58. The business has a fifty day moving average price of $2.93 and a 200 day moving average price of $2.85. The stock has a market capitalization of $68.17 million, a P/E ratio of -1.20 and a beta of 0.70.

Institutional Trading of PetMed Express

Several large investors have recently bought and sold shares of PETS. Occudo Quantitative Strategies LP purchased a new position in shares of PetMed Express in the second quarter worth $51,000. Oxford Asset Management LLP purchased a new position in PetMed Express in the 2nd quarter worth $55,000. CIBC Private Wealth Group LLC purchased a new position in PetMed Express in the 3rd quarter worth $75,000. Bridgeway Capital Management LLC lifted its position in PetMed Express by 96.2% during the 2nd quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company’s stock worth $135,000 after acquiring an additional 20,000 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of PetMed Express by 59.3% in the first quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company’s stock valued at $139,000 after purchasing an additional 12,360 shares during the period. Hedge funds and other institutional investors own 73.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PETS. Wall Street Zen cut shares of PetMed Express from a “hold” rating to a “sell” rating in a report on Saturday, October 18th. Weiss Ratings restated a “sell (e+)” rating on shares of PetMed Express in a research note on Monday, December 29th. One research analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Sell” and a consensus price target of $3.20.

PetMed Express Company Profile

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.